<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id><journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id><journal-id journal-id-type="publisher-id">abd</journal-id><journal-title-group><journal-title>Anais Brasileiros de Dermatologia</journal-title></journal-title-group><issn pub-type="ppub">0365-0596</issn><issn pub-type="epub">1806-4841</issn><publisher><publisher-name>Sociedade Brasileira de Dermatologia</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29364437</article-id><article-id pub-id-type="pmc">5786395</article-id><article-id pub-id-type="doi">10.1590/abd1806-4841.20176154</article-id><article-categories><subj-group subj-group-type="heading"><subject>Investigation</subject></subj-group></article-categories><title-group><article-title>Prepubertal and postpubertal vitiligo: a multivariate comparative
study in 375 patients<xref ref-type="fn" rid="fn1">*</xref></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Khurrum</surname><given-names>Huma</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>AlGhamdi</surname><given-names>Khalid M</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="c1"/></contrib></contrib-group><aff id="aff1">
<label>1</label> Vitiligo Research Chair, College of Medicine, King Saud University,
Riyadh, Saudi Arabia.</aff><aff id="aff2">
<label>2</label> Dermatology Department, College of Medicine, King Saud University,
Riyadh, Saudi Arabia.</aff><author-notes><corresp id="c1">Mailing address: Khalid M AlGhamdi, Vitiligo Research Chair,
Dermatology Department, College of Medicine, King Saud University, 11322 Riyadh,
Saudi Arabia. E-mail: <email>kmgderm@gmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Nov-Dec</season><year>2017</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Nov-Dec</season><year>2017</year></pub-date><volume>92</volume><issue>6</issue><fpage>811</fpage><lpage>815</lpage><history><date date-type="received"><day>13</day><month>6</month><year>2016</year></date><date date-type="accepted"><day>09</day><month>8</month><year>2016</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution Non-Commercial No Derivative License, which
permits unrestricted non-commercial use, distribution, and reproduction in
any medium provided the original work is properly cited and the work is not
changed in any way.</license-p></license></permissions><abstract><sec><title>Background</title><p>The onset of vitiligo during childhood is common. Limited data exist that
compare the clinical associations of prepubertal and postpubertal vitiligo
in Arabs.</p></sec><sec><title>Objective</title><p>To compare the clinical profile of pre and postpubertal onset vitiligo.</p></sec><sec><title>Methods</title><p>A cross-sectional observational study was conducted. The Vitiligo European
Task Force questionnaire was completed for each patient.</p></sec><sec><title>Results</title><p>A total of 375 patients were included; 199 had postpubertal vitiligo (&#x0003e;12
years), and 176 had prepubertal onset vitiligo (&#x0003c;12years). There were
more females in the prepubertal group (49%) than in the postpubertal group
(29%), p-value &#x0003c;0.001. The prepubertal group has had more involvement
than the postpubertal group (45% vs 30%, p=0.004). Only 8 cases of segmental
vitiligo were observed; five were observed in the prepubertal group of
patients. Female gender (OR=2.3; 95% CI:1.5, 3.5), presence of halo nevus
(OR=2.2; 95% CI:1.1, 4.4) and face involvement (OR=1.9; 95% CI:1.2, 2.9)
were positively associated with prepubertal vitiligo. Stress, as an onset
factor, was positively associated (OR=0.51; 95% CI:0.3, 0.8) with
postpubertal onset vitiligo.</p></sec><sec><title>Study limitations</title><p>A possible selection bias toward more severe vitiligo cases can be a
limitation, because the study was conducted in a clinic specialized in
vitiligo. Moreover, a likelihood of false recall bias cannot be
excluded.</p></sec><sec><title>Conclusions</title><p>Our data present clinical evidence that vitiligo behaves mostly the same way
in the prepubertal group as in the postpubertal group. However, female
over-representation, more face involvement and more halo nevi were observed
in prepubertal vitiligo, while stress was more prevalent as an aggravating
factor in postpubertal vitiligo patients.</p></sec></abstract><kwd-group><kwd>Nevus, halo</kwd><kwd>Stress, psychological</kwd><kwd>Vitiligo</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Vitiligo is mainly an acquired depigmentary disorder affecting around 1% of the
world's population.<sup><xref rid="r1" ref-type="bibr">1</xref>-<xref rid="r3" ref-type="bibr">3</xref></sup> In 25% of the cases, it begins prior
to 14 years of age.<sup><xref rid="r4" ref-type="bibr">4</xref></sup></p><p>The mean age of onset varied from 4 to 8 years among different studies. The mean age
of onset in Caucasians is 24 years.<sup><xref rid="r5" ref-type="bibr">5</xref>-<xref rid="r7" ref-type="bibr">7</xref></sup> Vitiligo can occur
in infants as young as 3 months old. Congenital vitiligo has been described
previously.<sup><xref rid="r8" ref-type="bibr">8</xref></sup> Prepubertal
vitiligo may differ from postpubertal vitiligo.</p><p>To date, few reports have addressed differences between true paediatric
vitiligo/prepubertal onset vitiligo (before the age of 12) and later-onset vitiligo
(after the age of 12, postpubertal onset vitiligo).<sup><xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r10" ref-type="bibr">10</xref></sup></p><p>There is an inadequate number of studies comparing various associated clinical
factors with both prepubertal and postpubertal vitiligo forms. The present study
shows the results of a cross-sectional observational study, after having received
ethical clearance from the institutional board review of King Khalid University
hospital, aimed at identifying factors associated with prepubertal and postpubertal
onset vitiligo using univariate and multivariate logistic regression analyses.</p></sec><sec sec-type="methods"><title>METHODS</title><p>This research conducted an observational cross-sectional study in the dermatology
clinic at King Khalid University Hospital between January 1, 2008, and July 1, 2012.
Ethics committee approval was obtained from the university's review board. All
patients with vitiligo, defined as an acquired progressive depigmentation according
to the Vitiligo European Task Force (VETF) definition, were enrolled in this
study.<sup><xref rid="r11" ref-type="bibr">11</xref></sup></p><p>The VETF questionnaires were completed by each vitiligo patient attending the clinic
on his/her first visit.<sup><xref rid="r12" ref-type="bibr">12</xref></sup> The VETF
form provided a wide range of demographic and clinical information, including sex,
age, age at onset of vitiligo, phototype, site of involvement and distribution
patterns, Koebner phenomenon (KP, defined in the VETF grid as depigmentation on
scars), presence of halo nevi, family history of vitiligo, personal and/or family
history of chronic autoimmune/autoinflammatory diseases (thyroid disease, atopy,
rheumatoid arthritis, psoriasis, type 1 diabetes mellitus, alopecia areata or
inflammatory bowel disease), family history of premature greying of hair (more than
50% of white hair before the age of 40), emotional stress at onset and response to
treatment, if any.</p><sec><title>Statistical analysis</title><p>Patient characteristics were summarized as counts and percentages, and were
compared between prepubertal onset (&#x02264; 12 years) and postpubertal onset
vitiligo (&#x0003e; 12 years) using a chi-squared test. Logistic regression analysis
was used to study the effect of risk factors on the age at onset of prepubertal
vitiligo, and odds ratios with 95% confidence intervals were computed. The
analyses were performed without adjustments for each of the potential risk
factors and were further adjusted by entering clinically important covariates in
the adjusted multivariable model. All p-values were considered to be
statistically significant at the 5% level. Hosmer and Lemeshow goodness-of-fit
was used to test the adequacy of the logistic regression model. Statistical
analyses were performed using STATA statistical software version 13 (StataCorp.
2013. Stata Statistical Software: Release 13. College Station, TX: StataCorp
LP).</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Demographic and clinical characteristics of patients</title><p>A total of 375 patients were included, of which 176 (male 90, female 86) were in
the prepubertal group, and 199 (male 140, female 59) were in the postpubertal
vitiligo onset group (<xref ref-type="table" rid="t1">Table 1</xref>). More
males were observed in the postpubertal group (70.4% vs. 51%), while females
were observed more in the prepubertal group than in the postpubertal group (49%
vs. 29.6%), p value &#x0003c; 0.001. Disease durations of &#x02264; 3 years were 37.2%
and 39.4% in the prepubertal and postpubertal groups, respectively. Emotional
stress as an aggravating factor was observed more in the postpubertal group
(24.1%) when compared to the prepubertal group (9.7%). The presence of one or
more halo nevi was observed more often (13.1%) in the prepubertal group when
compared to the postpubertal group (6.5%). With regards to the previous episode
of spontaneous regimentation, there was a significant difference of 9.7% and
19.6%, respectively, in the prepubertal and postpubertal groups. The prepubertal
vitiligo group is associated with a family history of premature greying of hairs
(p= 0.05).</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Description of patient characteristics according to the age of vitiligo
onset (&#x02264; 12 years vs &#x0003e; 12 years) (n=375)</p></caption><table frame="void" rules="rows" style="background-color:#EBE5EB"><colgroup span="1"><col width="50%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/></colgroup><thead><tr><th style="border-color:#FFFFFF" rowspan="3" align="center" valign="top" colspan="1">Demographic and clinical data</th><th style="border-bottom:hidden" colspan="2" align="center" rowspan="1">Prepubertal onset of vitiligo</th><th style="border-bottom:hidden" colspan="2" align="center" rowspan="1">Postpubertal onset of vitiligo</th><th style="border-color:#FFFFFF" rowspan="3" align="center" valign="top" colspan="1">p</th></tr><tr><th colspan="2" align="center" rowspan="1">(&#x02264; 12 years), n=176</th><th colspan="2" align="center" rowspan="1">(&#x0003e;12 years) n=199</th></tr><tr><th align="center" rowspan="1" colspan="1">n</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">n</th><th align="center" rowspan="1" colspan="1">%</th></tr></thead><tbody style="border-color:#FFFFFF"><tr><td align="left" rowspan="1" colspan="1"><bold>Gender (n=369)</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">90 </td><td align="center" rowspan="1" colspan="1">51.1</td><td align="center" rowspan="1" colspan="1">140 </td><td align="center" rowspan="1" colspan="1">70.4</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">86 </td><td align="center" rowspan="1" colspan="1">48.9</td><td align="center" rowspan="1" colspan="1">59 </td><td align="center" rowspan="1" colspan="1">29.6</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Duration of disease (n=370)</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">0.67</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02264; 3y</td><td align="center" rowspan="1" colspan="1">64 </td><td align="center" rowspan="1" colspan="1">37.2</td><td align="center" rowspan="1" colspan="1">78 </td><td align="center" rowspan="1" colspan="1">39.4</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e; 3y</td><td align="center" rowspan="1" colspan="1">108 </td><td align="center" rowspan="1" colspan="1">62.8</td><td align="center" rowspan="1" colspan="1">120 </td><td align="center" rowspan="1" colspan="1">60.6</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Koebner phenomenon (n=371)</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">0.56</td></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">47 </td><td align="center" rowspan="1" colspan="1">26.9</td><td align="center" rowspan="1" colspan="1">58 </td><td align="center" rowspan="1" colspan="1">29.6</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">128 </td><td align="center" rowspan="1" colspan="1">73.1</td><td align="center" rowspan="1" colspan="1">138 </td><td align="center" rowspan="1" colspan="1">70.4</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Emotional stress as onset factor
(n=375)</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Triggering</td><td align="center" rowspan="1" colspan="1">31 </td><td align="center" rowspan="1" colspan="1">17.6</td><td align="center" rowspan="1" colspan="1">36 </td><td align="center" rowspan="1" colspan="1">18.1</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Aggravating factor</td><td align="center" rowspan="1" colspan="1">17 </td><td align="center" rowspan="1" colspan="1">9.7</td><td align="center" rowspan="1" colspan="1">48 </td><td align="center" rowspan="1" colspan="1">24.1</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Has no relation</td><td align="center" rowspan="1" colspan="1">128 </td><td align="center" rowspan="1" colspan="1">72.7</td><td align="center" rowspan="1" colspan="1">115 </td><td align="center" rowspan="1" colspan="1">57.8</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Presence of halo nevus (n=375)</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" rowspan="1" colspan="1">None</td><td align="center" rowspan="1" colspan="1">153 </td><td align="center" rowspan="1" colspan="1">86.9</td><td align="center" rowspan="1" colspan="1">186 </td><td align="center" rowspan="1" colspan="1">93.5</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">One or more</td><td align="center" rowspan="1" colspan="1">23 </td><td align="center" rowspan="1" colspan="1">13.1</td><td align="center" rowspan="1" colspan="1">13 </td><td align="center" rowspan="1" colspan="1">6.5</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Previous episode of repigmentation
(n=375)</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">None</td><td align="center" rowspan="1" colspan="1">73 </td><td align="center" rowspan="1" colspan="1">41.5</td><td align="center" rowspan="1" colspan="1">78 </td><td align="center" rowspan="1" colspan="1">39.2</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Spontaneous</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">9.7</td><td align="center" rowspan="1" colspan="1">39 </td><td align="center" rowspan="1" colspan="1">19.6</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Following Rx</td><td align="center" rowspan="1" colspan="1">84 </td><td align="center" rowspan="1" colspan="1">47.7</td><td align="center" rowspan="1" colspan="1">82 </td><td align="center" rowspan="1" colspan="1">41.2</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">After sun exposure</td><td align="center" rowspan="1" colspan="1">2 </td><td align="center" rowspan="1" colspan="1">1.1</td><td align="center" rowspan="1" colspan="1">0 </td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Type of vitiligo (n=370)</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">0.332</td></tr><tr><td align="left" rowspan="1" colspan="1">Focal</td><td align="center" rowspan="1" colspan="1">35 </td><td align="center" rowspan="1" colspan="1">20.2</td><td align="center" rowspan="1" colspan="1">53 </td><td align="center" rowspan="1" colspan="1">26.9</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Segmental</td><td align="center" rowspan="1" colspan="1">5 </td><td align="center" rowspan="1" colspan="1">2.8</td><td align="center" rowspan="1" colspan="1">3 </td><td align="center" rowspan="1" colspan="1">1.5</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Acrofacial</td><td align="center" rowspan="1" colspan="1">37 </td><td align="center" rowspan="1" colspan="1">21.4</td><td align="center" rowspan="1" colspan="1">34 </td><td align="center" rowspan="1" colspan="1">17.3</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Generalised vitiligo</td><td align="center" rowspan="1" colspan="1">73 </td><td align="center" rowspan="1" colspan="1">42.2</td><td align="center" rowspan="1" colspan="1">77 </td><td align="center" rowspan="1" colspan="1">39.1</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Mucosal</td><td align="center" rowspan="1" colspan="1">1 </td><td align="center" rowspan="1" colspan="1">0.5</td><td align="center" rowspan="1" colspan="1">5 </td><td align="center" rowspan="1" colspan="1">2.5</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Mixed</td><td align="center" rowspan="1" colspan="1">22 </td><td align="center" rowspan="1" colspan="1">12.7</td><td align="center" rowspan="1" colspan="1">25 </td><td align="center" rowspan="1" colspan="1">12.7</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table></table-wrap><p>No significant difference was observed between a family history of vitiligo or
autoimmune disease with respect to the vitiligo onset in either group. The
personal history of autoimmune disease was similar in both groups (<xref ref-type="table" rid="t2">Table 2</xref>). Generalised vitiligo was the
predominant type of disease observed during consultation for both groups. Facial
involvement was identified more often in the prepubertal group (44.9%) when
compared to the postpubertal group (30.2%).</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Description of other patient characteristics according to the age of
vitiligo onset (&#x02264; 12 years versus &#x0003e; 12 years ) (n=375)</p></caption><table frame="void" rules="rows" style="background-color:#EBE5EB"><colgroup span="1"><col width="50%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/></colgroup><thead><tr><th rowspan="3" align="left" colspan="1">&#x000a0;</th><th colspan="2" align="center" rowspan="1">Prepubertal onset of vitiligo</th><th align="center" colspan="2" rowspan="1">Postpubertal onset of vitiligo</th><th rowspan="3" align="center" valign="top" colspan="1">p</th></tr><tr><th colspan="2" align="center" rowspan="1">(&#x02264; 12 years) n=176</th><th align="center" colspan="2" rowspan="1">(&#x02264; 12 years) n=199</th></tr><tr><th align="center" rowspan="1" colspan="1">n</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">n</th><th align="center" rowspan="1" colspan="1">%</th></tr></thead><tbody style="border-color:#FFFFFF"><tr><td align="left" rowspan="1" colspan="1"><bold>Personal history of autoimmune disease
(n=375)</bold></td><td style="border-bottom-width:thin;border-bottom-style:solid;border-color:#000000" align="center" rowspan="1" colspan="1">&#x000a0;</td><td style="border-bottom-width:thin;border-bottom-style:solid;border-color:#000000" align="center" rowspan="1" colspan="1">&#x000a0;</td><td style="border-bottom-width:thin;border-bottom-style:solid;border-color:#000000" align="center" rowspan="1" colspan="1">&#x000a0;</td><td style="border-bottom-width:thin;border-bottom-style:solid;border-color:#000000" align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">0.44</td></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">9.1</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">11.6</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">160</td><td align="center" rowspan="1" colspan="1">90.9</td><td align="center" rowspan="1" colspan="1">176</td><td align="center" rowspan="1" colspan="1">88.4</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Family history of premature greying of hair
(n=375)</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">28</td><td align="center" rowspan="1" colspan="1">15.9</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">9.6</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">148</td><td align="center" rowspan="1" colspan="1">84.1</td><td align="center" rowspan="1" colspan="1">180</td><td align="center" rowspan="1" colspan="1">90.4</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Family history of vitiligo
(n=371)</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">0.47</td></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">86</td><td align="center" rowspan="1" colspan="1">49.1</td><td align="center" rowspan="1" colspan="1">89</td><td align="center" rowspan="1" colspan="1">45.4</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">89</td><td align="center" rowspan="1" colspan="1">50.9</td><td align="center" rowspan="1" colspan="1">107</td><td align="center" rowspan="1" colspan="1">54.6</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Family history of autoimmune disease
(n=375)</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">0.47</td></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">51</td><td align="center" rowspan="1" colspan="1">28.9</td><td align="center" rowspan="1" colspan="1">51</td><td align="center" rowspan="1" colspan="1">25.6</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">125</td><td align="center" rowspan="1" colspan="1">71.0</td><td align="center" rowspan="1" colspan="1">148</td><td align="center" rowspan="1" colspan="1">74.4</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table></table-wrap></sec><sec><title>Logistic Regression Analysis</title><p>Results of univariate logistic regression of very early onset for clinically
important patient characteristics are presented in <xref ref-type="table" rid="t3">table 3</xref>. Female gender (OR=2.3; 95% CI:1.5, 3.5), presence
of halo nevus (OR=2.2; 95% CI:1.1, 4.4) and face involvement (OR=1.9; 95%
CI:1.2, 2.9) were positively associated with early-onset vitiligo. Stress as an
onset factor was positively associated (OR=0.51; 95% CI:0.3, 0.8) with
postpubertal onset vitiligo. No significant difference was observed in the
distribution of previous episodes of spontaneous repigmentation, disease
duration, Koebner's phenomenon, personal and family history of premature greying
of hair, and family history of vitiligo and/or autoimmune disease.</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Univariate logistic regression for prepubertal (&#x02264; 12) vs
postpubertal onset of vitiligo (&#x0003e; 12) (n=357)</p></caption><table frame="void" rules="rows" style="background-color:#EBE5EB"><colgroup span="1"><col width="60%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/></colgroup><thead><tr><th style="border-color:#FFFFFF" rowspan="2" align="left" valign="bottom" colspan="1">Gender (female)</th><th align="center" rowspan="1" colspan="1">OR</th><th align="center" rowspan="1" colspan="1">95% CI</th><th align="center" rowspan="1" colspan="1">N</th><th align="center" rowspan="1" colspan="1">P</th></tr><tr><th style="border-color:#FFFFFF" align="center" rowspan="1" colspan="1">2.26</th><th style="border-color:#FFFFFF" align="center" rowspan="1" colspan="1">1.5-3.5</th><th style="border-color:#FFFFFF" align="center" rowspan="1" colspan="1">375</th><th style="border-color:#FFFFFF" align="center" rowspan="1" colspan="1">&#x0003c;0.001</th></tr></thead><tbody style="border-color:#FFFFFF"><tr><td align="left" rowspan="1" colspan="1"><bold>Previous episode of spontaneous
repigmentation (yes/no)</bold></td><td align="center" rowspan="1" colspan="1">0.909</td><td align="center" rowspan="1" colspan="1">0.6 - 1.4</td><td align="center" rowspan="1" colspan="1">375</td><td align="center" rowspan="1" colspan="1">0.65</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Presence of Koebner phenomenon (yes/
no)</bold></td><td align="center" rowspan="1" colspan="1">0.873</td><td align="center" rowspan="1" colspan="1">0.6 - 1.4</td><td align="center" rowspan="1" colspan="1">371</td><td align="center" rowspan="1" colspan="1">0.56</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Stress as an aggravating factor (yes/
no)</bold></td><td align="center" rowspan="1" colspan="1">0.513</td><td align="center" rowspan="1" colspan="1">0.3- 0.8</td><td align="center" rowspan="1" colspan="1">375</td><td align="center" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Disease duration (&#x0003e; 3 years/ &#x02264; 3
years)</bold></td><td align="center" rowspan="1" colspan="1">1.096</td><td align="center" rowspan="1" colspan="1">0.7 - 1.7</td><td align="center" rowspan="1" colspan="1">370</td><td align="center" rowspan="1" colspan="1">0.67</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Halo nevus (yes/ no)</bold></td><td align="center" rowspan="1" colspan="1">2.150</td><td align="center" rowspan="1" colspan="1">1.1 - 4.4</td><td align="center" rowspan="1" colspan="1">375</td><td align="center" rowspan="1" colspan="1">0.035</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Family history of premature greying of hair
(yes/ no)</bold></td><td align="center" rowspan="1" colspan="1">1.792</td><td align="center" rowspan="1" colspan="1">0.9 - 3.3</td><td align="center" rowspan="1" colspan="1">375</td><td align="center" rowspan="1" colspan="1">0.06</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Family history of vitiligo (yes/
no)</bold></td><td align="center" rowspan="1" colspan="1">1.162</td><td align="center" rowspan="1" colspan="1">0.8 - 1.7</td><td align="center" rowspan="1" colspan="1">371</td><td align="center" rowspan="1" colspan="1">0.47</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Personal history of autoimmune disease (yes/
no)</bold></td><td align="center" rowspan="1" colspan="1">0.765</td><td align="center" rowspan="1" colspan="1">0.4 - 1.5</td><td align="center" rowspan="1" colspan="1">375</td><td align="center" rowspan="1" colspan="1">0.44</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Family history of autoimmune disease (yes/
no)</bold></td><td align="center" rowspan="1" colspan="1">1.184</td><td align="center" rowspan="1" colspan="1">0.7 - 1.9</td><td align="center" rowspan="1" colspan="1">375</td><td align="center" rowspan="1" colspan="1">0.47</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Face involvement (yes/no)</bold></td><td align="center" rowspan="1" colspan="1">1.887</td><td align="center" rowspan="1" colspan="1">1.2-2.9</td><td align="center" rowspan="1" colspan="1">375</td><td align="center" rowspan="1" colspan="1">0.003</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>OR- unadjusted odds ratio; CI- Confidence interval</p></fn></table-wrap-foot></table-wrap><p>When all of the patient characteristics were included simultaneously in the
logistic regression analysis, female gender (OR=2.4; 95% CI:1.6, 3.9,
P&#x0003c;0.001), stress as an aggravating factor (OR=0.45; 95% CI:0.3,0.7, P=0.001),
halo nevus (OR=2.4; 95% CI:1.1, 5.4, P=0.03) and face involvement (OR=1.8; 95%
CI:1.1, 2.8, P=0.01) remained statistically significant (<xref ref-type="table" rid="t4">Table 4</xref>). The logistic regression model results using
Hosmer-Lemeshow goodness-of fit were good (p=0.77).</p><table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Multivariable logistic regression for prepubertal (&#x02264; 12 years) vs
postpubertal onset of vitiligo (&#x0003e; 12 years) (n=357)</p></caption><table frame="void" rules="rows" style="background-color:#EBE5EB"><colgroup span="1"><col width="40%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr style="border-color:#FFFFFF"><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">AOR</th><th align="center" rowspan="1" colspan="1">95% CI</th><th align="center" rowspan="1" colspan="1">P</th></tr></thead><tbody style="border-color:#FFFFFF"><tr><td align="left" rowspan="1" colspan="1"><bold>Gender (female)</bold></td><td align="center" rowspan="1" colspan="1">2.47</td><td align="center" rowspan="1" colspan="1">1.6-3.9</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Previous episode of spontaneous
repigmentation (yes/no)</bold></td><td align="center" rowspan="1" colspan="1">0.78</td><td align="center" rowspan="1" colspan="1">0.5 - 1.3</td><td align="center" rowspan="1" colspan="1">0.31</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Presence of Koebner phenomenon (yes/
no)</bold></td><td align="center" rowspan="1" colspan="1">0.99</td><td align="center" rowspan="1" colspan="1">0.6 - 1.7</td><td align="center" rowspan="1" colspan="1">0.98</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Stress as an aggravating factor (yes/
no)</bold></td><td align="center" rowspan="1" colspan="1">0.45</td><td align="center" rowspan="1" colspan="1">0.3- 0.7</td><td align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Disease duration (&#x0003e; 3 years/ &#x02264; 3
years)</bold></td><td align="center" rowspan="1" colspan="1">1.28</td><td align="center" rowspan="1" colspan="1">0.8 - 2.1</td><td align="center" rowspan="1" colspan="1">0.30</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Halo nevus (yes/ no)</bold></td><td align="center" rowspan="1" colspan="1">2.41</td><td align="center" rowspan="1" colspan="1">1.1 - 5.4</td><td align="center" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Family history of premature greying of hair
(yes/ no)</bold></td><td align="center" rowspan="1" colspan="1">1.37</td><td align="center" rowspan="1" colspan="1">0.7 - 2.6</td><td align="center" rowspan="1" colspan="1">0.35</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Family history of vitiligo (yes/
no)</bold></td><td align="center" rowspan="1" colspan="1">1.18</td><td align="center" rowspan="1" colspan="1">0.8 - 1.9</td><td align="center" rowspan="1" colspan="1">0.46</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Personal history of autoimmune disease (yes/
no)</bold></td><td align="center" rowspan="1" colspan="1">0.59</td><td align="center" rowspan="1" colspan="1">0.3 - 1.3</td><td align="center" rowspan="1" colspan="1">0.18</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Family history of autoimmune disease (yes/
no)</bold></td><td align="center" rowspan="1" colspan="1">1.19</td><td align="center" rowspan="1" colspan="1">0.7 - 1.9</td><td align="center" rowspan="1" colspan="1">0.48</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Face involvement (yes/no)</bold></td><td align="center" rowspan="1" colspan="1">1.79</td><td align="center" rowspan="1" colspan="1">1.1-2.8</td><td align="center" rowspan="1" colspan="1">0.01</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>AOR- Adjusted Odds ratio; CI= Confidence interval</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>The purpose of this study was to compare prepubertal and postpubertal vitiligo in
clinical and epidemiologic settings. In our study, a female gender preference was
noted for prepubertal vitiligo. Other studies also report a female preponderance of
57%<sup><xref rid="r5" ref-type="bibr">5</xref>-<xref rid="r7" ref-type="bibr">7</xref></sup> to 63%,<sup><xref rid="r3" ref-type="bibr">3</xref></sup> and in our study, this percentage was even higher (66%). Other
studies express equal numbers of patients for both genders.<sup><xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r5" ref-type="bibr">5</xref></sup> Whether girls are overrepresented in childhood, compared with
late-onset vitiligo, is also ambiguous. We found a significant difference in the
female:male ratio between prepubertal and postpubertal vitiligo.</p><p>Childhood vitiligo was reported to vary from adults by AOR-Adjusted Odds ratio; CI=
Confidence interval showing a higher incidence in females; segmental vitiligo was
more common and was less frequently linked to other systemic autoimmune and
endocrine disorders.<sup><xref rid="r12" ref-type="bibr">12</xref></sup> The present
study also found more segmental cases in the prepubertal group. Regarding the
preliminary presentation site of prepubertal vitiligo, our results are in agreement
with previous studies that reported the head and neck area as the most common site
and the upper extremities as the least common site.<sup><xref rid="r13" ref-type="bibr">13</xref></sup> Psychological stress has been associated with
vitiligo onset and progression. In one study, 44% of the patients with vitiligo
referred to stress as the cause of their disease.<sup><xref rid="r14" ref-type="bibr">14</xref></sup> A significant difference in the mean number of
stressful events between patients with vitiligo and control subjects has also been
reported.<sup><xref rid="r15" ref-type="bibr">15</xref></sup> In a
paediatric vitiligo population, disease onset has been connected to psychological
aspects in 57% of the patients.<sup><xref rid="r16" ref-type="bibr">16</xref></sup>
Patients with postpubertal vitiligo associated stress with a statistically
significant higher frequency (p=0.003). Nevertheless, we cannot eliminate a recall
bias in this difference, because patients with childhood vitiligo might be unable to
recall stress events.</p><p>Vitiligo may be associated with other autoimmune disorders, such as alopecia areata,
diabetes mellitus, pernicious anaemia, Addison's disease and thyroid disorder. One
Indian study associated autoimmune disorders in 1.3% of the children with
vitiligo.<sup><xref rid="r7" ref-type="bibr">7</xref></sup> Numerous authors
have reported vitiligo-associated autoimmune disorders occurring solely in children
suffering from NSV.<sup><xref rid="r17" ref-type="bibr">17</xref></sup> In the study
by Hann <italic>et al.</italic><sup><xref rid="r13" ref-type="bibr">13</xref></sup>,
associated autoimmune disorders were found in 3.4% of children with SV.</p><p>In our study, the prevalence of thyroid diseases was not significantly dissimilar in
patients with prepubertal vitiligo when compared to patients with postpubertal
disease. An interesting finding that, to the best of our knowledge, has not been
reported before is that the prepubertal vitiligo group is associated with a family
history of the premature greying of hair (p= 0.05).</p><p>Compared to the general population, patients with vitiligo have higher rates of a
positive family history of the disease.<sup><xref rid="r12" ref-type="bibr">12</xref>,<xref rid="r18" ref-type="bibr">18</xref></sup> In our study,
49.1% of the patients with childhood-onset vitiligo and 45.1% of the patients with
later onset vitiligo had a positive family history of the disease. No discrimination
was found between the two groups, as has also been reported elsewhere.<sup><xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r9" ref-type="bibr">9</xref></sup> This study found no disparity in the positive family history
rate between patients with early versus late disease onset.</p><p>A positive family history of thyroid disease has been described in 32% to 43% of
children with vitiligo, but in our study, no significant difference was observed in
the family history of vitiligo in either group.<sup><xref rid="r12" ref-type="bibr">12</xref>,<xref rid="r19" ref-type="bibr">19</xref></sup> A positive family
history for the premature greying of hairs is more common in the prepubertal
vitiligo group.</p><p>In an earlier study, a strong connection was found between halo nevi
associated-non-segmental vitiligo and the premature greying of hair, suggesting that
the latter may involve an autoimmune process.<sup><xref rid="r20" ref-type="bibr">20</xref></sup> This hypothesis may be reinforced by the fact that in our
population of vitiligo with prepubertal onset, halo nevus was observed more often
(p=0.03).</p><p>Our study found that patients with a prepubertal onset of vitiligo had a lesser
chance of spontaneous repigmentation (p=0.02). This may possibly support the early
treatment of children with vitiligo, in which it is well-known that in vitiligo,
treatment is more effective in fresh lesions as compared to older lesions.<sup><xref rid="r20" ref-type="bibr">20</xref></sup></p><p>The limitations of this study include a possible selection bias toward more severe
vitiligo cases, given that the study was conducted in a clinic specialized in
vitiligo. Additionally, a possibility of false recall bias cannot be excluded, as
patients with childhood vitiligo might be incapable of accurately remembering the
period of disease onset. The strong points of this study consist of a large sample
size, the first of its kind in the Middle East, and the advanced statistical methods
used in the analysis.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>Prepubertal onset vitiligo, when compared to postpubertal vitiligo, has distinct
clinical features. No associations of thyroid abnormalities or atopic dermatitis
were found with prepubertal or postpubertal vitiligo. Stress as an aggravating
factor was observed more often in the postpubertal group, while prepubertal vitiligo
patients had more face involvement. Further epidemiological studies are needed to
establish the relationships of different factors; in particular, genetic studies
should be taken into account for both prepubertal and postpubertal vitiligo. Future
analysis of various factors are needed in order to establish the cause of vitiligo
and to guide professionals toward a proper target therapy.</p></sec></body><back><fn-group><fn fn-type="other" id="fn1"><label>*</label><p>Work performed at the King Khalid university hospital.</p></fn><fn fn-type="supported-by"><p>Financial support: The project was financially supported in part by King Saud
University, Vice Dean of Research Chairs.</p></fn><fn fn-type="COI-statement"><p>Conflict of interest: None.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Hann</surname><given-names>SK</given-names></name><name><surname>Nordlund</surname><given-names>JJ</given-names></name></person-group><source>Vitiligo: A Monograph on the Basic and Clinical Science</source><year>2000</year><publisher-loc>Oxford, London</publisher-loc><publisher-name>Blackwell Science Ltd</publisher-name></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howitz</surname><given-names>J</given-names></name><name><surname>Brodthagen</surname><given-names>H</given-names></name><name><surname>Schwartz</surname><given-names>M</given-names></name><name><surname>Thomsen</surname><given-names>K</given-names></name></person-group><article-title>Prevalence of vitiligo. Epidemiological survey on the Isle of
Bornholm, Denmark</article-title><source>Arch Dermatol</source><year>1977</year><volume>113</volume><fpage>47</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">831622</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>S</given-names></name><name><surname>Kang</surname><given-names>HC</given-names></name><name><surname>Hahm</surname><given-names>JH</given-names></name></person-group><article-title>Characteristics of vitiligo in Korean children</article-title><source>Pediatr Dermatol</source><year>2000</year><volume>17</volume><fpage>189</fpage><lpage>193</lpage><pub-id pub-id-type="pmid">10886749</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kakourou</surname><given-names>T</given-names></name></person-group><article-title>Vitiligo in children</article-title><source>World J Pediatr</source><year>2009</year><volume>5</volume><fpage>265</fpage><lpage>268</lpage><pub-id pub-id-type="pmid">19911140</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>JB</given-names></name><name><surname>Ma</surname><given-names>SS</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>XJ</given-names></name></person-group><article-title>Profile of childhood vitiligo in China: an analysis of 541
patients</article-title><source>Pediatr Dermatol</source><year>2006</year><volume>23</volume><fpage>114</fpage><lpage>116</lpage><pub-id pub-id-type="pmid">16650215</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaisankar</surname><given-names>TJ</given-names></name><name><surname>Baruah</surname><given-names>MC</given-names></name><name><surname>Garg</surname><given-names>BR</given-names></name></person-group><article-title>Vitiligo in children</article-title><source>Int J Dermatol</source><year>1992</year><volume>31</volume><fpage>621</fpage><lpage>623</lpage><pub-id pub-id-type="pmid">1459757</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Handa</surname><given-names>S</given-names></name><name><surname>Dogra</surname><given-names>S</given-names></name></person-group><article-title>Epidemiology of childhood vitiligo a study of 625 patients from
north India</article-title><source>Pediatr Dermatol</source><year>2003</year><volume>20</volume><fpage>207</fpage><lpage>210</lpage><pub-id pub-id-type="pmid">12787267</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kedward</surname><given-names>AL</given-names></name><name><surname>Gawkrodger</surname><given-names>DJ</given-names></name></person-group><article-title>Congenital stable symmetrical type vitiligo in a patient whose
mother developed vitiligo during pregnancy</article-title><source>Eur J Dermatol</source><year>2008</year><volume>18</volume><fpage>353</fpage><lpage>353</lpage></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halder</surname><given-names>RM</given-names></name><name><surname>Grimes</surname><given-names>PE</given-names></name><name><surname>Cowan</surname><given-names>CA</given-names></name><name><surname>Enterline</surname><given-names>JA</given-names></name><name><surname>Chakrabarti</surname><given-names>SG</given-names></name><name><surname>Kenney</surname><given-names>JA Jr</given-names></name></person-group><article-title>Childhood vitiligo</article-title><source>J Am Acad Dermatol</source><year>1987</year><volume>16</volume><fpage>948</fpage><lpage>954</lpage><pub-id pub-id-type="pmid">3584578</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicolaidou</surname><given-names>E</given-names></name><name><surname>Antoniou</surname><given-names>C</given-names></name><name><surname>Miniati</surname><given-names>A</given-names></name><name><surname>Lagogianni</surname><given-names>E</given-names></name><name><surname>Matekovits</surname><given-names>A</given-names></name><name><surname>Stratigos</surname><given-names>A</given-names></name><etal/></person-group><article-title>Childhood- and later-onset vitiligo have diverse epidemiologic
and clinical characteristics</article-title><source>J Am Acad Dermatol</source><year>2012</year><volume>66</volume><fpage>954</fpage><lpage>958</lpage><pub-id pub-id-type="pmid">21982634</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ta&#x000ef;eb</surname><given-names>A</given-names></name><name><surname>Picardo</surname><given-names>M</given-names></name><collab>VETF Members</collab></person-group><article-title>The definition and assessment of vitiligo: a consensus report of
the Vitiligo European Task Force</article-title><source>Pigment Cell Res</source><year>2007</year><volume>20</volume><fpage>27</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">17250545</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pajvani</surname><given-names>U</given-names></name><name><surname>Ahmad</surname><given-names>N</given-names></name><name><surname>Wiley</surname><given-names>A</given-names></name><name><surname>Levy</surname><given-names>RM</given-names></name><name><surname>Kundu</surname><given-names>R</given-names></name><name><surname>Mancini</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>The relationship between family medical history and childhood
vitiligo</article-title><source>J Am Acad Dermatol</source><year>2006</year><volume>55</volume><fpage>238</fpage><lpage>244</lpage><pub-id pub-id-type="pmid">16844505</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hann</surname><given-names>SK</given-names></name><name><surname>Lee</surname><given-names>HJ</given-names></name></person-group><article-title>Segmental vitiligo: clinical findings in 208
patients</article-title><source>J Am Acad Dermatol</source><year>1996</year><volume>35</volume><fpage>671</fpage><lpage>674</lpage><pub-id pub-id-type="pmid">8912558</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ezzedine</surname><given-names>K</given-names></name><name><surname>Diallo</surname><given-names>A</given-names></name><name><surname>L&#x000e9;aut&#x000e9;-Labr&#x000e8;ze</surname><given-names>C</given-names></name><name><surname>Mossalayi</surname><given-names>D</given-names></name><name><surname>Gauthier</surname><given-names>Y</given-names></name><name><surname>Bouchtnei</surname><given-names>S</given-names></name><etal/></person-group><article-title>Multivariate analysis of factors associated with early-onset
segmental and nonsegmental vitiligo: a prospective observational study of
213 patients</article-title><source>Br J Dermatol</source><year>2011</year><volume>165</volume><fpage>44</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">21410675</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manolache</surname><given-names>L</given-names></name><name><surname>Benea</surname><given-names>V</given-names></name></person-group><article-title>Stress in patients with alopecia areata and
vitiligo</article-title><source>J Eur Acad Dermatol Venereol</source><year>2007</year><volume>21</volume><fpage>921</fpage><lpage>928</lpage><pub-id pub-id-type="pmid">17659001</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ezzedine</surname><given-names>K</given-names></name><name><surname>Diallo</surname><given-names>A</given-names></name><name><surname>L&#x000e9;aut&#x000e9;-Labr&#x000e8;ze</surname><given-names>C</given-names></name><name><surname>Seneschal</surname><given-names>J</given-names></name><name><surname>Boniface</surname><given-names>K</given-names></name><name><surname>Cario-Andr&#x000e9;</surname><given-names>M</given-names></name><etal/></person-group><article-title>Pre- vs. post-pubertal onset of vitiligo: multivariate analysis
indicates atopic diathesis association in pre-pubertal onset
vitiligo</article-title><source>Br J Dermatol</source><year>2012</year><volume>167</volume><fpage>490</fpage><lpage>495</lpage><pub-id pub-id-type="pmid">22512840</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazereeuw-Hautier</surname><given-names>J</given-names></name><name><surname>Bezio</surname><given-names>S</given-names></name><name><surname>Mahe</surname><given-names>E</given-names></name><name><surname>Bodemer</surname><given-names>C</given-names></name><name><surname>Eschard</surname><given-names>C</given-names></name><name><surname>Viseux</surname><given-names>V</given-names></name><etal/></person-group><article-title>Groupe de Recherche Clinique en Dermatologie P&#x000e9;diatrique
(GRCDP). Segmental and nonsegmental childhood vitiligo has distinct clinical
characteristics: a prospective observational study</article-title><source>J Am Acad Dermatol</source><year>2010</year><volume>62</volume><fpage>945</fpage><lpage>949</lpage><pub-id pub-id-type="pmid">20466172</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barona</surname><given-names>MI</given-names></name><name><surname>Arrun&#x000e1;tegui</surname><given-names>A</given-names></name><name><surname>Falabella</surname><given-names>R</given-names></name><name><surname>Alzate</surname><given-names>A</given-names></name></person-group><article-title>An epidemiologic case-control study in a population with
vitiligo</article-title><source>J Am Acad Dermatol</source><year>1995</year><volume>33</volume><fpage>621</fpage><lpage>625</lpage><pub-id pub-id-type="pmid">7673496</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prcic</surname><given-names>S</given-names></name><name><surname>Duran</surname><given-names>V</given-names></name><name><surname>Poljacki</surname><given-names>M</given-names></name></person-group><article-title>Vitiligo in childhood</article-title><source>Med Pregl</source><year>2002</year><volume>55</volume><fpage>475</fpage><lpage>480</lpage><pub-id pub-id-type="pmid">12712889</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>DY</given-names></name><name><surname>Kim</surname><given-names>CR</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name></person-group><article-title>Recent onset vitiligo on acral areas treated with phototherapy:
need of early treatment</article-title><source>Photodermatol Photoimmunol Photomed</source><year>2010</year><volume>26</volume><fpage>266</fpage><lpage>268</lpage><pub-id pub-id-type="pmid">21175856</pub-id></element-citation></ref></ref-list></back></article>